BIO-11002

BIO-11002 is a preclinical-stage peptide drug candidate being developed by BioMarck Pharmaceuticals for the treatment of various neoplasms (cancer). It is designed as an inhibitor of the Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) protein, a key regulatory molecule involved in cell motility, cytoskeletal structure, and inflammatory signaling. By targeting the MARCKS protein, BIO-11002 aims to suppress MARCKS-driven oncogenic processes and the release of inflammatory cytokines, which are often implicated in cancer progression and metastasis. The compound is part of BioMarck's broader platform of patent-protected peptides targeting the MARCKS pathway for difficult-to-treat inflammatory and malignant conditions.